COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05142527

Not reported

Not reported

2021-12-02

Withdrawn

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

phase 2 inclusion criteria: informed consent understood and signed prior to screening procedures healthy male or non-pregnant, non-lactating female 18 years of age or older, inclusive on the day of dosing subject willing to comply with and be available for all protocol procedures for the duration of the study subject determined by medical history, physical examination, and clinical judgement of the principal investigator (pi) to be eligible for inclusion in the study by meeting all the inclusion criteria and no exclusion criteria subject with bmi ≥18.5 and ≤ 35 kg/m2 females of childbearing potential must have a negative urine pregnancy test on day 1 prior to dosing note: a woman is considered of childbearing potential unless post-menopausal (> or = 1 year without menses without other known or suspected cause and appropriately elevated fsh) or surgically sterilized via bilateral oophorectomy or hysterectomy. females of childbearing potential and males must agree to use medically effective contraception (methods with a failure rate of < 1% per year when used consistently and correctly) from screening until last dose. acceptable methods include: hormonal contraception including implants, injections or oral; two barrier methods, e.g., condom and cervical cap (with spermicide) or diaphragm (with spermicide); intrauterine device or intrauterine system; abstinence when this is the subject's preferred and usual lifestyle. subject agrees to not donate bone marrow, blood, and blood products for at least 3 months after dosing clinical laboratory results within normal ranges or are no greater than grade 1 and deemed not clinically significant by medical monitor and pi. (any subjects with results that are grade 2 or above according to toxicity table (modified from fda guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trial) will be excluded) subject willing to provide verifiable identification and has means to be contacted and to contact the principal investigator (pi) during the study. phase 2

history of chronic medical condition that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject history of diabetes (type 1 or type 2), cardiovascular disease, pulmonary disease, chronic obstructive pulmonary disease (copd) or asthma history of severe allergic reactions of any type to medications, bee stings, food, or environmental factors or hypersensitivity or reaction to immunoglobins known allergic reactions or history of anaphylaxis or any other serious adverse reactions to any of the study product components present in the formulation or in its processing, as listed in the investigator brochure known to have hiv, hbsag, or hcv per self-reported medical history febrile illness with temperature ≥38°c within 7 days of dosing. (subjects with acute febrile illness within 7 days of dosing may be rescreened no earlier than 7 days following resolution of symptoms). rapid sars cov-2 antigen nasopharyngeal swab is positive on day 1 prior to dosing or positive sars-cov-2 rt-pcr if result is received prior to dosing female subject who is pregnant or breastfeeding has previously received any coronavirus vaccine treatment with another investigational drug or licensed live vaccine within 30 days prior to or after planned enrollment. subjects will be informed of local availability and be eligible to obtain an authorized covid-19 vaccine at the time of enrollment and at any time during the study known history of covid-19 infection receipt of any antibody (e.g. tig, vzig, ivig, im gamma globulin, monoclonal antibody) or blood or plasma transfusion within 6 months or within 5 half-lives of the specific antibody product given history of solid organ or bone marrow transplantation active drug or alcohol use disorder or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements use of h1 antihistamines or beta-blockers within 5 days of dosing (prn use of h1 antihistamines may be acceptable after medical monitor approval) history of malignancy within 5 years of screening (with the exception of squamous or basal cell carcinomas of the skin, or malignancy which is considered cured with minimal risk of recurrence) plans to enroll or is already enrolled in another interventional study has contraindication to im injections or blood draws e.g., bleeding disorders, use of any anti-coagulants any specific condition that in the judgment of the pi precludes participation because it could affect subject safety is a study site employee or staff. note: site employees or staff include the pis and sub-investigators or staff who are supervised by the pi or sub-investigators phase 3 inclusion criteria informed consent understood and signed prior to screening procedures healthy male or non-pregnant, non-lactating female 18 years of age or older, inclusive on the day of dosing subject has willingness to comply with and be available for all protocol procedures for the duration of the study subjects determined by medical history, physical examination, and clinical judgement of the pi to be eligible for inclusion in the study by meeting all the inclusion criteria and no exclusion criteria subject with bmi ≥18.5 and ≤ 40 kg/m2 female subjects of childbearing potential must have a negative urine pregnancy test on day 1 prior to dosing. note: a woman is considered of childbearing potential unless post-menopausal (> or = 1 year without menses without other known or suspected cause and appropriately elevated fsh) or surgically sterilized via bilateral oophorectomy or hysterectomy females of childbearing potential must agree to use medically effective contraception (methods with a failure rate of < 1% per year when used consistently and correctly) from screening until last dose. acceptable methods include: hormonal contraception including implants, injections or oral; two barrier methods, e.g., condom and cervical cap (with spermicide) or diaphragm (with spermicide); intrauterine device or intrauterine system; abstinence when this is the subject's preferred and usual lifestyle subject agrees to not donate bone marrow, blood, and blood products for at least 3 months after dosing subjects' willingness to provide verifiable identification, have means to be contacted and to contact the pi during the study phase 3

2

Ology Bioservices

18

100

None

Healthy volunteers

N/A

0

Incidence and severity of reactogenicity through Day 7 and adverse events (AEs) through end of study (Phase 2);Incidence of SAEs and medically-attended AEs (Phase 2);Incidence of symptomatic, virologically confirmed COVID-19 (Phase 3);Occurrence of changes from baseline in physical examination, vital signs, and clinical safety laboratory values (Phase 2)

None

Phase 2/Phase 3

[{"arm_notes": "", "treatment_id": 35, "treatment_name": "Adm03820", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]